Team:MIT/Cas9-VP16
From 2013.igem.org
(Difference between revisions)
Line 28: | Line 28: | ||
Here, we describe the creation and testing of a Cas9-VP16 fusion protein. Current transcriptional level activators/repressors function by binding DNA at certain conserved sequences and influencing the transcriptional abilities of some nearby promoter. The issue with these current activators/repressors is that each one binds one unique DNA sequence. The GAL protein binds UAS sites, TetR binds TetO sites, LacI binds LacO sites, and so on. By using Cas9 as the DNA binding portion of a trans-activator, we can eliminate the need for specific binding sites by taking advantage of Cas9's unique ability to target most any DNA sequence as determined by its complexed guide RNA. The technology could be used to either target and activate endogenous sequences by creating a guide RNA which targets a sequence upstream of the promoter in question, or one could create many different guide RNAs which target different inducible promoters and activate multiple genes with one single trans-activator. Our project looks into creating a Cas9-VP16 protein and testing its ability to activate a minimal CMV promoter by targeting the fusion to two upstream binding sites using a complementary guide RNA. | Here, we describe the creation and testing of a Cas9-VP16 fusion protein. Current transcriptional level activators/repressors function by binding DNA at certain conserved sequences and influencing the transcriptional abilities of some nearby promoter. The issue with these current activators/repressors is that each one binds one unique DNA sequence. The GAL protein binds UAS sites, TetR binds TetO sites, LacI binds LacO sites, and so on. By using Cas9 as the DNA binding portion of a trans-activator, we can eliminate the need for specific binding sites by taking advantage of Cas9's unique ability to target most any DNA sequence as determined by its complexed guide RNA. The technology could be used to either target and activate endogenous sequences by creating a guide RNA which targets a sequence upstream of the promoter in question, or one could create many different guide RNAs which target different inducible promoters and activate multiple genes with one single trans-activator. Our project looks into creating a Cas9-VP16 protein and testing its ability to activate a minimal CMV promoter by targeting the fusion to two upstream binding sites using a complementary guide RNA. | ||
- | + | <div class= "section" id="diagram"> | |
+ | <h1>The Circuit</h1> | ||
<img src="https://static.igem.org/mediawiki/2013/a/a3/Constitutive_Circuit_Diagram.png" width="400" height="400"/> | <img src="https://static.igem.org/mediawiki/2013/a/a3/Constitutive_Circuit_Diagram.png" width="400" height="400"/> | ||
<br> | <br> | ||
+ | <div class= "section" id="data"> | ||
+ | <h1>The Data</h1> | ||
<img src="https://static.igem.org/mediawiki/2013/b/b0/Vp16.png" width="600" height="400"/> | <img src="https://static.igem.org/mediawiki/2013/b/b0/Vp16.png" width="600" height="400"/> | ||
<br> | <br> |